Mucinous borderline ovarian tumors with BRAF V600E mutation may have low risk for progression to invasive carcinomas

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-0711

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Mucinous borderline ovarian tumors with BRAF V600E mutation may have low risk for progression to invasive carcinomas ; volume:302 ; number:2 ; day:16 ; month:6 ; year:2020 ; pages:487-495 ; date:8.2020
Archives of gynecology and obstetrics ; 302, Heft 2 (16.6.2020), 487-495, 8.2020

Creator: Ohnishi, Kaori
Nakayama, Kentaro
Ishikawa, Masako
Ishibashi, Tomoka
Yamashita, Hitomi
Nakamura, Kohei
Minamoto, Toshiko
Iida, Kouji
Razia, Sultana
Ishikawa, Noriyoshi
Kyo, Satoru

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00404-020-05638-8

URN: urn:nbn:de:101:1-2020082323323720545913

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:58 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Ohnishi, Kaori
Nakayama, Kentaro
Ishikawa, Masako
Ishibashi, Tomoka
Yamashita, Hitomi
Nakamura, Kohei
Minamoto, Toshiko
Iida, Kouji
Razia, Sultana
Ishikawa, Noriyoshi
Kyo, Satoru
SpringerLink (Online service)

Other Objects (12)

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component

Hochschulschrift

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component

Hochschulschrift

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component

Hochschulschrift

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Mucinous borderline ovarian tumors with BRAF V600E mutation may have low risk for progression to invasive carcinomas

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms

Related objects

Reset password